Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Essure Court Cases Move Ahead, Clear Legal Obstacles

Executive Summary

Plaintiffs in a lawsuit alleging Bayer’s Essure contraceptive device caused patient injuries filed a revised complaint in California state courts this week. The coordinated proceedings include at least 3,000 patients, though no court date has yet been sent.

You may also be interested in...



Bayer Halts Essure Sales In EU As US FDA Relies On Study, Patient Warnings

Bayer AG said Sept. 18 it will not renew a CE mark for its Essure permanent contraceptive coils for women in EU countries, effectively halting sales of the product outside the US. The firm says its decision was "unrelated to product safety or efficacy," and driven by its commercial strategy. Meanwhile, US FDA calls for warnings and black box labels for Essure in the US, and says a Sec. 522 post-market study it ordered Bayer to complete "will help us better understand" thousands of complaints about the device.

Essure Panel Stresses Need For Patient Follow-Up, But Stressed-Out Patients Say, ‘Recall It’

An FDA advisory panel recommended a collection of activities to mitigate risk in the use of Bayer Healthcare’s Essure permanent contraceptive device, but dozens of patients describing hypersensitivity, extreme pain, insert migration, irregular bleeding, ectopic pregnancy and perforation events urged FDA to recall the device.

Preemption Questions Persist: Supreme Court Doesn’t Take Bait In Medtronic Case

The Supreme Court’s decision not to take up Stengel v. Medtronic could make device firms vulnerable to more product liability suits by leaving open questions about the federal preemption defense for PMA-approved devices. Meanwhile, the Obama administration recently issued a legal interpretation that, if adopted, would surely weaken the defense.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT121534

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel